Landing Page Software1. Grigoletto A, Marotti V, Tedeschini T, Campara B, Marigo I, Ingangi V, Pasut G. Improving the Therapeutic Potential of G-CSF through Compact Circular PEGylation Based on Orthogonal Conjugations. Biomacromol. 2023;XXXX. doi: 10.1021/acs.biomac.3c00543
2. Canato E, Grigoletto A, Zanotto I, Tedeschini T, Campara B, Quaglio G, Toffoli G, Mandracchia D, Dinarello A, Tiso N, Argenton F, Sayaf K, Guido M, Gabbia D, De Martin S, Pasut G. Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy. Adv Healthc Mater. 2023;XXXX. doi: 10.1002/adhm.202301650
3. Fongaro B, Campara B, Moscatiello GY, De Luigi A, Panzeri D, Sironi L, Bigini P, Carretta G, Miolo G, Pasut G, Polverino De Laureto P. Assessing the physicochemical stability and intracellular trafficking of mRNA-based COVID-19 vaccines. Int J Pharm. 2023;644:123319. doi: 10.1016/j.ijpharm.2023.123319
4. Pavan M, Fanti CD, Lucia AD, Canato E, Acquasaliente L, Sonvico F, Delgado J, Hicks A, Torrelles JB, Kulkarni V, Dwivedi V, Zanellato AM, Galesso D, Pasut G, Buttini F, Martinez-Sobrido L, Guarise C. Aerosolized sulfated hyaluronan derivatives prolong the survival of K18 ACE2 mice infected with a lethal dose of SARS-CoV-2. Eur J Pharm Sci. 2023;187:106489. doi: 10.1016/j.ejps.2023.106489.
5. Guarise C, Acquasaliente L, Pasut G, Pavan M, Soato M, Garofolin G, Beninatto R, Giacomel E, Sartori E, Galesso D. The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model. J Mech Behav Biomed Mater. 2023;143:105908. doi: 10.1016/j.jmbbm.2023.105908.
6. Kumar S, Florindo HF, Pasut G. Editorial: Highlights in nano-based drug delivery 2021/22. Front Med Technol. 2023;5:1130414. doi: 10.3389/fmedt.2023.1130414
7. Zanon E, De Cristofaro R, Franchini M, Morfini M, Pasut G, Molinari AC, Santoro C, Santoro RC, Coppola A, Rocino A. Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers. Blood Transfus. 2023 Jan 26. doi: 10.2450/2023.0235-22
8. Battista MR, Grigoletto A, Tedeschini T, Cellucci A, Colaceci F, Laufer R, Pasut G, Di Marco A. Efficacy of PEGylated ciliary neurotrophic factor superagonist variant in diet-induced obesity mice. PLoS ONE. 2022;17(3):e0265749. doi: 10.1371/journal.pone.0265749
9. Dodd A, Natfji AA, Evangelinos A, Grigoletto A, Pasut G, Beards F, Renshall L, Osborn HMI, Greco F, Harris LK. Conjugation to PEG as a Strategy to Limit the Uptake of Drugs by the Placenta: Potential Applications for Drug Administration in Pregnancy. Mol Pharm. 2022;19(1):345-353. doi: 10.1021/acs.molpharmaceut.1c00498.
10. Saggioro M, D'Agostino S, Gallo A, Crotti S, D'Aronco S, Corallo D, Veltri G, Martinez G, Grigoletto A, Tolomeo AM, Tafuro G, Agostini M, Aveic S, Serafin V, Semenzato A, Pasut G, Pozzobon M. A rhabdomyosarcoma hydrogel model to unveil cell-extracellular matrix interactions. Biomater Sci. 2021;10(1):124-137. doi: 10.1039/d1bm00929j.
11. Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, Pasut G. The role and the impact of polyethylene glycol on the anaphylactic reactions to the COVID-19 nano-vaccines. Nat Nanotech. 2021;16(11):1169-1171. doi: 10.1038/s41565-021-01001-3.
12. Tedeschini T, Campara B, Grigoletto A, Bellini M, Salvalaio M, Matsuno Y, Suzuki A, Yoshioka H, Pasut G. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Control Release. 2021;337:431-447. doi: 10.1016/j.jconrel.2021.07.041.
13. Grigoletto A, Martinez G, Gabbia D, Tedeschini T, Scaffidi M, De Martin S, Pasut G. Folic Acid-Targeted Paclitaxel-Polymer Conjugates Exert Selective Cytotoxicity and Modulate Invasiveness of Colon Cancer Cells. Pharmaceutics. 2021;13(7):929. doi: 10.3390/pharmaceutics13070929.
14. Gola A, Bernardi A, Pasut G, Musiał W. The Influence of Initiator Concentration on Selected Properties of Thermosensitive Poly(Acrylamide-co-2-Acrylamido-2-Methyl-1-Propanesulfonic Acid) Microparticles. Polymers (Basel). 2021;13(7):996. doi: 10.3390/polym13070996.
15. Dalla Pietà A, Carpanese D, Grigoletto A, Tosi A, Dalla Santa S, Pedersen GK, Christensen D, Meléndez-Alafort L, Barbieri V, De Benedictis P, Pasut G, Montagner IM, Rosato A. Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. Cell Mol Immunol. 2021;18(5):1197-1210. doi: 10.1038/s41423-021-00667-y.
16. Delfino D, Mori G, Rivetti C, Grigoletto A, Bizzotto G, Cavozzi C, Malatesta M, Cavazzini D, Pasut G, Percudani R. Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease. Biomolecules. 2021;11(3):410. doi: 10.3390/biom11030410.
17. Grigoletto A, Tedeschini T, Canato E, Pasut G. The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020:e1689. doi: 10.1002/wnan.1689.
18. Onuigbo E, Attama A, Canato E, Pasut G. Comparison of classical, stealth and super-stealth liposomes for intravenous delivery of lumefantrine: Formulation, characterization and pharmacodynamic study. Trop J Pharm Res. 2020;19:2247-2253. doi: 10.4314/tjpr.v19i11.1.
19. Maso K, Grigoletto A, Raccagni L, Bellini M, Marigo I, Ingangi V, Suzuki A, Hirai M, Kamiya M, Yoshioka H, Pasut G. Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers for protein conjugation. J Control Release. 2020;324:228-237. doi: 10.1016/j.jconrel.2020.05.015.
20. Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. J Clin Invest. 2020;130(5):2435-2450. doi: 10.1172/JCI131133.
21. Roselló-Catafau J, Panisello-Roselló A, Pasut G, Navasa M, Pirenne J, Adam R. Original and generic preservation solutions in organ transplantation. A new paradigm? Acta Cir Bras. 2020;35(1):e202000101. doi: 10.1590/s0102-865020200010000001.
22. Giacomini I, Ragazzi E, Pasut G, Montopoli M. The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance. Int J Mol Sci. 2020;21(3):E937. doi: 10.3390/ijms21030937.
23. Cilurzo F, Cristiano MC, Da Pian M, Cianflone E, Quintieri L, Paolino D, Pasut G. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine. Anticancer Agents Med Chem. 2019;19(12):1513-1522. doi: 10.2174/1871520619666190626114641.
24. Maso K, Montagner IM, Grigoletto A, Schiavon O, Rosato A, Pasut G. A non-covalent antibody complex for the delivery of anti-cancer drugs. Eur J Pharm Biopharm. 2019;142:49-60. doi: 10.1016/j.ejpb.2019.06.012.
25. Wahlich J, Desai A, Greco F, Hill K, Jones AT, Mrsny RJ, Pasut G, Perrie Y, Seib FP, Seymour LW, Uchegbu IF. Nanomedicines for the Delivery of Biologics. Pharmaceutics. 2019;11(5):E210. doi: 10.3390/pharmaceutics11050210.
26. Aneja R, Grigoletto A, Nangarlia A, Rashad AA, Wrenn S, Jacobson JM, Pasut G, Chaiken I. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes. J Pep Sci. 2019;25(4):e3155. doi: 10.1002/psc.3155.
27. Catanzaro D, Nicolosi S, Cocetta V, Salvalaio M, Pagetta A, Ragazzi E, Montopoli M, Pasut G. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. Oncotarget. 2018;9:16847-16860. doi: 10.18632/oncotarget.24708
28. Grigoletto A, Mero A, Yoshioka H, Schiavon O, Pasut G. Covalent immobilisation of transglutaminase: stability and applications in protein pegylation. J Drug Targeting. 2017;25:856-864. doi: 10.1080/1061186X.2017.1363211
29. Dalzoppo D, Di Paolo V, Calderan L, Pasut G, Rosato A, Caccuri AM, Quintieri L. Thiol-activated anticancer agents: the state of the art. Anti-Cancer Agents Med Chem. 2017;17:4-20.
30. Heath F, Newman A, Clementi C, Pasut G, Lin H, Stephens GJ, Whalley BJ, Osborn HMI, Greco F. A novel PEG-haloperidol conjugate with a non-degradable linker shows the feasibility of using polymer-drug conjugates in a non-prodrug fashion. Pol Chem. 2016;7:7204-7210. doi: 10.1039/c6py01418f
31. Montagner IM, Merlo A, Carpanese D, Dalla Pietà A, Mero A, Grigoletto A, Loregian A, Renier D, Campisi M, Zanovello P, Pasut G, Rosato A. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer. J Control Release. 2016;236:79-89. doi: 10.1016/j.jconrel.2016.06.033
32. Grigoletto A, Maso K, Mero A, Rosato A, Schiavon O, Pasut G. Drug and protein delivery by polymer conjugation. J Drug Deliv Sci Tech. 2016;32:132-141. doi: 10.1016/j.jddst.2015.08.006
33. Bejaoui M, Pantazi E, Calvo M, Folch-Puy E, Serafín A, Pasut G, Panisello A, Adam R, Roselló-Catafau J. Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury. Oxid Med Cell Longev. 2016;2016:9096549. doi: 10.1155/2016/9096549.
34. Pasut G, Panisello A, Folch-Puy E, Lopez A, Castro-Benítez C, Calvo M, Carbonell T, García-Gil A, Adam R, Roselló-Catafau J. Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury. World J Gastroenterol. 2016;22(28):6501-8. doi: 10.3748/wjg.v22.i28.6501.
35. Spolaore B, Raboni S, Satwekar AA, Grigoletto A, Mero A, Montagner IM, Rosato A, Pasut G, Fontana A. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues. Bioconjug Chem. 2016;27(11):2695-2706. doi: 10.1021/acs.bioconjchem.6b00468.
36. Mero A, Grigoletto A, Maso K, Yoshioka H, Rosato A, Pasut G. Site-selective enzymatic chemistry for polymer conjugation to protein lysine residues: pegylation of G-CSF at lysine-41. Pol Chem. 2016;7:6545-6553. doi: 10.1039/C6PY01616B
37. Grigoletto A, Mero A, Zanusso I, Schiavon O, Pasut G. Chemical and Enzymatic Site Specific pegylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hgh and PEG-Gln141-hgh Conjugates. Macromol Biosci. 2016;16(1):50-6. doi: 10.1002/mabi.201500282.
38. Montagner IM, Merlo A, Carpanese D, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, Rosato A. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience. 2015;2(4):373-81. doi: 10.18632/oncoscience.150.
39. Mero A, Campisi M, Caputo M, Cuppari C, Rosato A, Schiavon O, Pasut G. Hyaluronic acid as a protein polymeric carrier: An overview and a report on human growth hormone. Curr Drug Targets. 2015;16:1503-1511.
40. Tripodo G, Pasut G, Trapani A, Mero A, Lasorsa FM, Chlapanidas T, Trapani G, Mandracchia D. Inulin-d-α-Tocopherol Succinate (INVITE) Nanomicelles as a Platform for Effective Intravenous Administration of Curcumin. Biomacromolecules. 2015;16(2):550-557. doi: 10.1021/bm501616e.
41. Bejaoui M, Pantazi E, Folch-Puy E, Panisello A, Calvo M, Pasut G, Rimola A, Navasa M, Adam R, Roselló-Catafau J. Protective Effect of Intravenous High Molecular Weight Polyethylene Glycol on Fatty Liver Preservation. Biomed Res Int. 2015;2015:794287. doi: 10.1155/2015/794287.
42. Mero A, Campisi M, Favero M, Barbera C, Secchieri C, Dayer JM, Goldring MB, Goldring SR, Pasut G. A hyaluronic acid-salmon calcitonin conjugate for the local treatment of osteoarthritis: Chondro-protective effect in a rabbit model of early OA. J Control Release. 2014;187:30-8. doi: 10.1016/j.jconrel.2014.05.008.
43. Sosic A, Pasqualin M, Pasut G, Gatto B. Enzymatic formation of pegylated oligonucleotides. Bioconjug Chem. 2014;25(2):433-41. doi: 10.1021/bc400569z
44. Pasut G. PEGylation of biological molecules and potential benefits: Pharmacological properties of certolizumab pegol. Biodrugs. 2014;28:15-23. doi: 10.1007/s40259-013-0064-z.
45. Montagner IM, Merlo A, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, Rosato A. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS One. 2014;9(11):e112240. doi: 10.1371/journal.pone.0112240.
46. Pasut G, Paolino D, Celia C, Mero A, Joseph AS, Wolfram J, Cosco D, Schiavon O, Shen H, Fresta M. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release. 2014;199:106-113. doi: 10.1016/j.jconrel.2014.12.008.
47. Zaouali MA, Bejaoui M, Calvo M, Folch-Puy E, Pantazi E, Pasut G, Rimola A, Ben Abdennebi H, Adam R, Roselló-Catafau J (2014). Polyethylene glycol rinse solution: An effective way to prevent ischemia-reperfusion injury. World J Gastroenterol. 2014;20(43):16203-14. doi: 10.3748/wjg.v20.i43.16203.
48. Pasut, G. Polymers for protein conjugation. Polymers. 2014;6:160-178. doi: 10.1016/j.jddst.2015.08.006.
49. Dall'Olmo L, Fassan M, Dassie E, Scarpa M, Realdon S, Cavallin F, Cagol M, Battaglia G, Pizzi M, Guzzardo V, Franceschinis E, Pasut G, Rugge M, Zaninotto G, Realdon N, Castoro C. Role of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo study. PloS One. 2014:9e112240. doi: 10.1371/journal.pone.0112862.
50. Da Silva Freitas D, Mero A, Pasut G. Chemical and enzymatic site specific pegylation of hgh. Bioconjug Chem. 2013;24(3):456-63. doi: 10.1021/bc300594y.
51. Mero A, Pasqualin M, Campisi M, Renier D, Pasut G. Conjugation of hyaluronan to proteins. Carbohydr. Polym. 2013;92:2163-2170. doi: 10.1016/j.carbpol.2012.11.090.
52. Licciardi M, Pasut G, Amato G, Scialabba C, Mero A, Montopoli M, Cavallaro G, Schiavon O, Giammona G. PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. Eur J Pharm Biopharm. 2013;84(1):21-8. doi: 10.1016/j.ejpb.2012.12.011.
53. Miller K, Clementi C, Polyak D, Eldar-Boock A, Benayoun L, Barshack I, Shaked Y, Pasut G, Satchi-Fainaro R. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials. 2013;34(15):3795-806. doi: 10.1016/j.biomaterials.2013.01.052.
54. Greco F, Arif I, Botting R, Fante C, Quintieri L, Clementi C, Schiavon O, Pasut G. Polysialic acid as a drug carrier: Evaluation of a new polysialic acid–epirubicin conjugate and its comparison against established drug carriers. Pol Chem. 2013;4:1600-1609. doi: 10.1039/C2PY20876H.
55. Mero A, Fang Z, Pasut G, Veronese FM, Viegas TX. Selective conjugation of poly (2-ethyl 2-oxazoline) to granulocyte colony stimulating factor. J Control Release. 2012;159(3):353-61. doi: 10.1016/j.jconrel.2012.02.025.
56. Pasut G, Veronese FM. State of the art in pegylation: The great versatility achieved after forty years of research. J Control Release. 2012;161(2):461-72. doi: 10.1016/j.jconrel.2011.10.037.
57. Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G. Dendritic poly (ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm. 2011;8(4):1063-72. doi: 10.1021/mp2001445.
58. Ishino T, Economou NJ, McFadden K, Zaks-Zilberman M, Jost M, Baxter S, Contarino MR, Harrington AE, Loll PJ, Pasut G, Lievens S, Tavernier J, Chaiken I. A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Biochemistry. 2011;50(35):7546-56. doi: 10.1021/bi2009135.
59. Mero A, Ishino T, Chaiken I, Veronese FM, Pasut G. Multivalent and flexible PEG-nitrilotriacetic acid derivatives for non-covalent protein pegylation. Pharm Res. 2011;28(10):2412-21. doi: 10.1007/s11095-011-0468-8.
60. Mero A, Schiavon M, Veronese FM, Pasut G. A new method to increase selectivity of transglutaminase mediated pegylation of salmon calcitonin and human growth hormone. J Control Release. 2011;154(1):27-34. doi: 10.1016/j.jconrel.2011.04.024.
61. Turner KM, Pasut G, Veronese FM, Boyce A, Walsh G. Stabilization of a supplemental digestive enzyme by post-translational engineering using chemically-activated polyethylene glycol. Biotechnol Lett. 2011;33(3):617-21. doi: 10.1007/s10529-010-0474-7.
62. Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, Dizman B, Weimer R, Mero A, Pasut G, Veronese FM. Polyoxazoline: Chemistry, properties, and applications in drug delivery. Bioconjug Chem. 2011;22(5):976-86. doi: 10.1021/bc200049d.
63. Canal F, Vicent MJ, Pasut G, Schiavon O. Relevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates. J Control Release. 2010;146(3):388-99. doi: 10.1016/j.jconrel.2010.05.027.
64. Pasut G, Veronese FM. Improvement of drug therapy by covalent PEG conjugation: an overview from a research laboratory. Isr J Chem. 2010;50:151-159. doi: 10.1002/ijch.201000019
65. Canevari M, Castagliuolo I, Brun P, Cardin M, Schiavon M, Pasut G, Veronese FM. Poly (ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm. 2009;368(1-2):171-7. doi: 10.1016/j.ijpharm.2008.09.058.
66. Meléndez-Alafort L, Nadali A, Pasut G, Zangoni E, De Caro R, Cariolato L, Giron MC, Castagliuolo I, Veronese FM, Mazzi U. Detection of sites of infection in mice using 99mtc-labeled PN2S-PEG conjugated to UBI and 99mtc-UBI: A comparative biodistribution study. Nucl Med Biol. 2009;36(1):57-64. doi: 10.1016/j.nucmedbio.2008.10.011.
67. Mero A, Schiavon O, Pasut G, Veronese FM, Emilitri E, Ferruti P. A biodegradable polymeric carrier based on PEG for drug delivery. J Bioact Compatible Polym. 2009;24, 220-234. Doi: 10.1177/0883911509103783.
68. Pasut G, Greco F, Mero A, Mendichi R, Fante C, Green RJ, Veronese FM. Polymer− drug conjugates for combination anticancer therapy: Investigating the mechanism of action. J Med Chem. 2009;52(20):6499-502. doi: 10.1021/jm900804m.
69. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev. 2009;61(13):1177-88. doi: 10.1016/j.addr.2009.02.010.
70. Pasut G, Veronese FM. Pegylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc). 2009;45:687-695.
71. Mero A, Pasut G, Dalla Via L, Fijten MW, Schubert US, Hoogenboom R, Veronese FM. Synthesis and characterization of poly (2-ethyl 2-oxazoline)-conjugates with proteins and drugs: Suitable alternatives to PEG-conjugates? J Control Release. 2008;125(2):87-95. doi: 10.1016/j.jconrel.2007.10.010.
72. Pasut G, Mero A, Caboi F, Scaramuzza S, Sollai L, Veronese FM. A new PEG-beta-alanine active derivative for releasable protein conjugation. Bioconjug Chem. 2008;19(12):2427-31. doi: 10.1021/bc800281s.
73. Pasut G, Canal F, Dalla Via L, Arpicco S, Veronese FM, Schiavon O. Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid. J Control Release. 2008;127(3):239-48. doi: 10.1016/j.jconrel.2008.02.002.
74. Pasut G, Sergi M, Veronese FM. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev. 2008 Jan 3;60(1):69-78. doi: 10.1016/j.addr.2007.04.018.
75. Veronese FM, Pasut G. Pegylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discov Today Technol. 2008;5(2-3):e57-64. doi: 10.1016/j.ddtec.2009.02.002.
76. Pasut G, Caboi F, Schrepfer R, Tonon G, Schiavon O, Veronese FM. New active poly (ethylene glycol) derivative for amino coupling. React Funct Polym. 2007;67:529-539. doi: 10.1021/bc2006847
77. Pasut G, Veronese F. Polymer–drug conjugation, recent achievements and general strategies. Prog Polym Sci. 2007;32:933-961. doi: 10.1016/j.progpolymsci.2007.05.008
78. Pasut G, Veronese FM. Second-generation pharmaceutical proteins-EUFEPS workshop on optimizing biotech medicines. Idrugs. 2007;10:162-164.
79. Santucci L, Mencarelli A, Renga B, Ceccobelli D, Pasut G, Veronese FM, Distrutti E, Fiorucci S. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs. 2007;18(9):1081-91. doi: 10.1097/CAD.0b013e3281db8322.
80. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasut G. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem. 2007;18(6):1824-30. doi: 10.1021/bc070123+.
81. Berna M, Dalzoppo D, Pasut G, Manunta M, Izzo L, Jones AT, Duncan R, Veronese FM. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: Synthesis, characterization and cellular uptake. Biomacromolecules. 2006;7(1):146-53. doi: 10.1021/bm050480s.
82. Bertuglia S, Veronese FM, Pasut G. Polyethylene glycol and a novel developed polyethylene glycol-nitric oxide normalize arteriolar response and oxidative stress in ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2006;291(4):H1536-44. doi: 10.1152/ajpheart.01114.2005.
83. Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A, Fiorucci S. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: The case of NO-pegylated epirubicin. FASEB J. 2006;20(6):765-7. doi: 10.1096/fj.05-4452fje.
84. Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, Schiavon O, Summerford C, Tirk A, Veronese FM, Vincenzi V, Wu G. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates. Biomacromolecules. 2005;6(2):914-26. doi: 10.1021/bm049381p.
85. Bersani C, Berna M, Pasut G, Veronese FM. PEG-metronidazole conjugates: Synthesis, in vitro and in vivo properties. Farmaco. 2005;60(9):783-8. doi: 10.1016/j.farmac.2005.04.015.
86. Pasut G, Scaramuzza S, Schiavon O, Mendichi R, Veronese FM. PEG-epirubicin conjugates with high drug loading. J Bioact Compatible Polym. 2005;20:213-230. doi: 10.1177/0883911505053377
87. Veronese FM, Pasut, G. Pegylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8. doi: 10.1016/S1359-6446(05)03575-0.
88. Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R. PEG-doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem. 2005;16(4):775-84. doi: 10.1021/bc040241m.
89. Ishino T, Pasut G, Scibek J, Chaiken I. Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. J Biol Chem. 2004;279(10):9547-56. doi: 10.1074/jbc.M309327200.
90. Pasut G, Guiotto A, Veronese FM. Protein, peptide and non-peptide drug pegylation for therapeutic application. Expert Opin Ther Pat. 2004;14:859-894. doi: 10.1517/13543776.14.6.859
91. Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM. PEG–Ara-C conjugates for controlled release. Eur J Med Chem. 2004;39(2):123-33. doi: 10.1016/j.ejmech.2003.10.005.
92. Visentin R, Pasut G, Veronese FM, Mazzi U. Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3-diphenylphosphinopropionyl)glycyl]cysteine ligand with poly(ethylene glycol). Bioconjug Chem. 2004;15(5):1046-54. doi: 10.1021/bc049896d.
93. Furin A, Guiotto A, Baccichetti F, Pasut G, Deuschel C, Bertani R, Veronese FM. Synthesis, characterization and preliminary cytotoxicity assays of poly (ethylene glycol)–malonato–Pt–DACH conjugates. Eur J Med Chem. 2003;38(7-8):739-49. doi: 10.1016/s0223-5234(03)00114-4.
Landing Page Software